Controversies in the Therapy of Early-Stage Breast Cancer

Controversies in the Therapy of Early-Stage Breast Cancer Mary Cianfrocca, William J. Gradishar Oncologist 2005; 10: 766-779 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in breast cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Select appropriate adjuvant therapies for patients with early-stage breast cancer. Describe the evolving role of taxanes in the adjuvant therapy of early-stage breast cancer. Discuss the evolving role of aromatase inhibitors in the adjuvant therapy of early-stage breast cancer. Discuss the controversies that remain in the treatment of early-stage breast cancer. Interpret the recent data supporting the use of trastuzumab in the adjuvant setting for patients with HER-2-positive, early-stage breast cancer. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Nov. 28, 2005 Most Recent Review: Nov. 28, 2005* Most Recent Update: Nov. 28, 2005 Date Credit Expires: Nov. 28, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.